OBD — Oxford Biodynamics Share Price
Last trade - 00:00- £27.26m
- £28.45m
- £0.51m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.5 | ||
| Price to Tang. Book | 6.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 53.44 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.92% | ||
| Return on Equity | -250.51% | ||
| Operating Margin | -1971.57% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.91 | 0.46 | 0.34 | 0.15 | 0.51 | n/a | n/a | -15.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.
Directors
- Matthew Wakefield NEC (61)
- Jon Anthony Joseph Burrows CEO (58)
- Paul Stockdale CFO
- Alexandre Akoulitchev CSO (56)
- Stephen Diggle NED
- David Holbrook NID (59)
- Last Annual
- September 30th, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- April 25th, 2007
- Public Since
- December 6th, 2016
- No. of Employees
- 45
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 311,855,650
- Address
- 26 Beaumont Street, OXFORD, OX4 2WB
- Web
- https://www.oxfordbiodynamics.com/
- Phone
- +44 1865518910
- Auditors
- Grant Thornton UK LLP
Latest News for OBD
Upcoming Events for OBD
Half Year 2024 Oxford Biodynamics PLC Earnings Release
Similar to OBD
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 19:16 UTC, shares in Oxford Biodynamics are trading at 8.74p. This share price information is delayed by 15 minutes.
Shares in Oxford Biodynamics last closed at 8.74p and the price had moved by -43.52% over the past 365 days. In terms of relative price strength the Oxford Biodynamics share price has underperformed the FTSE All Share Index by -44.5% over the past year.
The overall consensus recommendation for Oxford Biodynamics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Oxford Biodynamics does not currently pay a dividend.
Oxford Biodynamics does not currently pay a dividend.
Oxford Biodynamics does not currently pay a dividend.
To buy shares in Oxford Biodynamics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 8.74p, shares in Oxford Biodynamics had a market capitalisation of £27.26m.
Here are the trading details for Oxford Biodynamics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: OBD
Based on an overall assessment of its quality, value and momentum Oxford Biodynamics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oxford Biodynamics. Over the past six months, its share price has underperformed the FTSE All Share Index by -77.07%.
As of the last closing price of 8.74p, shares in Oxford Biodynamics were trading -55.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oxford Biodynamics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 8.74p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oxford Biodynamics' management team is headed by:
- Matthew Wakefield - NEC
- Jon Anthony Joseph Burrows - CEO
- Paul Stockdale - CFO
- Alexandre Akoulitchev - CSO
- Stephen Diggle - NED
- David Holbrook - NID